Osteoblasts: Novel roles in orchestration of skeletal architecture

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 9, 2003, Pages 1301-1305

  Mackie, E J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Osteoblast; Osteoclast; Osteocyte; Osteoid

Indexed keywords

COLLAGEN TYPE 1; GLYCOPROTEIN; PROTEIN; PROTEOGLYCAN; SCLEROPROTEIN;

APOPTOSIS; BONE MARROW; BONE STRUCTURE; CALCIUM HOMEOSTASIS; CELL DIFFERENTIATION; CELL FUNCTION; CELLULAR DISTRIBUTION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOLOGY; PERIOSTEUM; REVIEW; SKELETON;

EID: 0037706865     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(03)00107-9     Document Type: Review

References (15)

1. Aubin, J. E., & Triffitt, J. T. (2002). Mesenchymal stem cells and osteoblast differentiation. In J. P. Bilezikian, L. G. Raisz, & G.A. Rodan (Eds.), Principles of bone biology (Vol. 1, pp. 59-81). San Diego: Academic Press.
2. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346:2002;1513-1521.
3. Gehron Robey, P. (2002). Bone matrix proteoglycans and glycoproteins. In J. P. Bilezikian, L. G. Raisz, & G. A. Rodan (Eds.), Principles of bone biology (Vol. 1, pp. 225-237). San Diego: Academic Press.
4. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M., Oexle K., Marcelino J., Suwairi W., Heeger S., Sabatakos G.et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 107:2001;513-523.
5. Hock, J. M., Fitzpatrick, L. A., & Bilezikian, J. B. (2002). Actions of parathyroid hormone. In J. P. Bilezikian, L. G. Raisz, & G. A. Rodan (Eds.), Principles of bone biology (Vol. 1, pp. 463-481). San Diego: Academic Press.
6. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104:1999;439-446.
7. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A. 2nd, Hartmann C., Li L., Hwang T.H., Brayton C.F., Lang R.A., Karsenty G., Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in LRP5, a Wnt coreceptor. J. Cell Biol. 157:2002;303-314.
8. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y., Hu X.et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70:2002;11-19.
9. Mackie E.J., Ramsey S. Modulation of osteoblast behaviour by tenascin. J. Cell. Sci. 109:1996;1597-1604.
10. Marks, S. C., & Odgren, P. R. (2002). Structure and development of the skeleton. In J. P. Bilezikian, L. G. Raisz, & G. A. Rodan (Eds.), Principles of bone biology (Vol. 1, pp. 3-15). San Diego: Academic Press.
11. Prêle C.M., Horton M.A., Caterina P., Stenbeck G. Identification of the molecular mechanisms contributing to polarized trafficking in osteoblasts. Exp. Cell. Res. 282:2003;24-34.
12. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
13. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell. 111:2002;305-317.
14. Udagawa N., Takahashi N., Jimi E., Matsuzaki K., Tsurukai T., Itoh K., Nakagawa N., Yasuda H., Goto M., Tsuda E., Higashio K., Gillespie M.T., Martin T.J., Suda T. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-kappa B ligand. Bone. 25:1999;517-523.
15. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3597-3602.